Everolimus adjunctive therapy for refractory partial-onset seizures in tuberous sclerosis complex

Phase 3, randomised, double-blind trial of everolimus in tuberous sclerosis complex (TSC) and epilepsy (3 arms), sponsored by Novartis. Primary endpoint: Reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase. Started Nov 2013; status: active, not recruiting.